Chemotherapy with doxorubicin, etoposide and cyclophosphamide (DEC) in ovarian cancer persistent after platinum-based treatment.

[1]  M. Markman,et al.  Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Rubin,et al.  Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Crumpler,et al.  Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer. , 1991, American journal of obstetrics and gynecology.

[4]  P. Schein,et al.  Hexamethylmelamine as a single second‐line agent in ovarian cancer , 1990, Gynecologic oncology.

[5]  G. Sutton,et al.  Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Redman,et al.  Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. , 1989, British Journal of Cancer.